Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

Breast Cancer Clinical Trial

Official title:

MRI Evaluation of Breast Tumor Growth and Treatment Response

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00474604
• Other study ID #: VICC BRE 0588
• Secondary ID: P30CA068485VU-VI
• Status: Completed
• Phase: N/A
• Start date: March 2006
• Est. completion date: April 25, 2023

Study information

• Verified date: November 2023
• Source: Vanderbilt-Ingram Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Diagnostic procedures, such as MRI, may help diagnose breast cancer. It may also help doctors predict a patient's response to treatment. PURPOSE: This clinical trial is studying breast MRI in women with known or suspected breast cancer and in healthy participants.

Description:

OBJECTIVES: - Develop and combine advanced, quantitative, multiparametric magnetic resonance imaging methods (i.e., dynamic contrast-enhanced MRI [DCE-MRI], diffusion-weighted MRI [DW-MRI], and magnetic resonance spectroscopy [MRS]) to characterize breast tumors in women with known or suspected breast cancer. - Identify surrogate biomarkers that can guide diagnosis and treatment of breast cancer using these methods. - Correlate biochemical information obtained from magnetic resonance analysis with clinical, radiologic, and pathologic findings in these patients. - Establish an imaging data bank that includes information on DCE-MRI, DW-MRI, and MRS findings in these patients and in healthy participants. OUTLINE: Quantitative, multi-parametric magnetic imaging methods will be employed for breast imaging for the following subjects: - Group A: Healthy volunteers who undergo up to 3 breast MRIs over 6 weeks. - Group B: Patients diagnosed with breast cancer who will: 1) undergo preoperative breast MRI followed by definitive surgery or 2) undergo MRI prior to initiating neoadjuvant chemotherapy, at 1-2 weeks after initiation of chemotherapy, and prior to definitive surgery. Clinical information, including radiologic and pathologic data, on all patients is collected for inclusion in the imaging data bank. After completion of the study, patients and healthy participants are followed periodically.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 209
• Est. completion date: April 25, 2023
• Est. primary completion date: April 25, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Women who satisfy the following conditions are the only subjects who will be eligible for

this study:

• Normal volunteers
• Subjects with known or suspected breast disease
• Subjects must have signed an approved consent form.
• Subjects must be = 18 years old.
• The protocol nurse will check with the patient that there is no h/o kidney disease
• Normal creatinine and estimated GFR* within 30 days under the following circumstances
• Had abnormal creatinine in the last 60 days
• Are over 60 years of age
• Has received chemotherapy within the past 30 days
• Has diabetes, HIV, renal disease or hx of renal cancer
• * GFR will be calculated using:

http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm

• Patients with an eGFR>90ml/min reported within 30 days, and who have not had intervening chemotherapy or other treatment or condition that might deteriorate renal function, may receive any gadolinium agent.

Exclusion Criteria:

• Children will be excluded from this study.
• Pregnant women and women who are breast feeding will be excluded from this study. (The Vanderbilt University Medical Center radiology "MRI Procedure Screening Form" will be used to identify and exclude subjects who are pregnant or breastfeeding. A urine pregnancy test/or serum beta HCG will also be performed for each pre-menopausal subject.)
• Subjects found to have any constitutionally present non-MR compatible ferromagnetic materials will be excluded from this study.
• Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study
• Subjects for whom an MRI is technically not feasible (e.g. breast volume, obesity)
• Subjects who have vascular access ports or other implanted devices rated as anything other than "Safe" or "Conditional 6"

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Procedure:
• diffusion-weighted magnetic resonance imaging
A scan will be performed.
• dynamic contrast-enhanced magnetic resonance imaging
A scan will be performed.
• magnetic resonance spectroscopic imaging
A scan will be performed.

Locations

Country	Name	City	State
United States	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt-Ingram Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial res — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of advanced, quantitative, multi-parametric magnetic resonance imaging (MRI) methods for characterizing breast tumors to develop potential surrogate imaging markers for diagnosis and prediction of treatment response	Quantitative, multi-parametric MRI imaging methods include Dynamic Contrast MRI, Diffusion Weighted MRI, and Magnetic Resonance Spectroscopy. Patients will include healthy female volunteers and women diagnosed with breast cancer. Time frames begin at study entry (healthy volunteers) , pre-surgical and pre- and post-chemotherapy (breast cancer patients)	on-study date and at 6 months, up to 4 years
Secondary	Correlation of biochemical data obtained from magnetic resonance analysis with clinical, radiological, and pathological findings	Biochemical data from advanced MRIs are compared and contrasted with findings from patients' clinical, chemotherapeutic, and radiologic treatments for breast cancer.	at 6 months
Secondary	Establishment of an imaging data bank	Results of advanced MRI imaging methods for subjects assessed after completion of all MRI procedures	at 6 months

External Links

•   Vanderbilt-Ingram Cancer Center, Find a Clinical Trial